Subject(s)
Chickenpox , Herpes Zoster , Child , China/epidemiology , Herpes Zoster/diagnosis , Herpes Zoster/epidemiology , Hospitals, Pediatric , HumansABSTRACT
BACKGROUND: The clinical use of gentamicin always lies in its antimicrobial activity in the past as an aminoglycoside antibiotic. However, in the past decade, there were considerable interests in therapeutic approaches in treating hereditary diseases. Some of the genodermatosis is caused by nonsense mutations that create premature termination codons and lead to the production of truncated or non-functional proteins. Gentamicin could induce readthrough of nonsense mutations and enable the synthesis of full-length proteins. We focus on previous publications on topical application of gentamicin and review its utility in genetic skin diseases. DATA SOURCES: We search the MEDLINE through PubMed, EMBASE databases, and the Clinical Trials Registry Platform from January 1960 to July 2020 using the key search terms "gentamicin, topical gentamicin, genodermatosis, genetic skin diseases". RESULTS: The application of gentamicin in genodermatosis yielded promising results, both in vivo and in vitro, including Nagashima-type palmoplantar keratosis, epidermolysis bullosa, Hailey-Hailey disease, hereditary hypotrichosis simplex of the scalp, etc. CONCLUSIONS: Topical gentamicin is a potential treatment option for genodermatosis caused by nonsense mutation.
Subject(s)
Gentamicins , Hypotrichosis , Anti-Bacterial Agents/therapeutic use , Codon, Nonsense , Gentamicins/therapeutic use , HumansABSTRACT
The field of pediatric dermatology treatment has been rich in new developments. Several recent therapeutic advances in pediatric dermatology have been made. This review will focus on critical approach to the new treatments for several entities encountered in pediatric dermatology. The use of biologics and small molecules in children with atopic dermatitis and psoriasis, exciting advances in the use of propranolol and other beta-blockers for the treatment of infantile hemangiomas, the use of sirolimus for vascular anomalies will be discussed.
Subject(s)
Skin Diseases/drug therapy , Adrenergic beta-Antagonists/therapeutic use , Biological Products/therapeutic use , Child , Dermatitis, Atopic/drug therapy , Hemangioma/drug therapy , Humans , Phosphodiesterase 4 Inhibitors/therapeutic use , Psoriasis/drug therapy , Sirolimus/therapeutic useABSTRACT
BACKGROUND: Atopic dermatitis (AD) is a common disease, which involves a disruption of the skin barrier function. Skin ceramide (CER) composition, which plays crucial roles in maintaining the barrier function of the stratum corneum, is changed in patients with AD. OBJECTIVE: The aim of this study was to identify and quantify skin CER subclasses in association with disease severity in pediatric patients with AD. METHODS: Two hundred thirteen patients were entered into the observational study. We compared their CER profiles using normal-phase high-performance liquid chromatography coupled with dynamic multiple reaction monitoring mass spectrometry. RESULTS: In total, 12 subclasses of CERs were identified. We found that 2 subclasses, that is, CER[AS] and CER[NS], were elevated (P = 0.007 and 0.012, respectively) and correlated with Severity Scoring of Atopic Dermatitis (P = 0.004 and 0.004, respectively). CONCLUSIONS: Skin CER abundances are changed in children with AD compared with control subjects.
